Archives of Clinical Microbiology

  • ISSN: 1989-8436
  • Journal h-index: 19
  • Journal CiteScore: 6.52
  • Journal Impact Factor: 0.72
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • The Global Impact Factor (GIF)
  • Open Archive Initiative
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Google Scholar
  • Scimago Journal Ranking
  • Secret Search Engine Labs
  • ResearchGate
Share This Page

Metadichol a novel nano lipid: A solution for the post-antibiotic era

August 23-24, 2017 | Toronto, Canada

P R Raghavan

Nanorx Inc., USA

Keynote: Arch Clin Microbiol


Metadichol is a nanoemulsion of long-chain alcohols found in many foods such as rice, sugar cane, wheat, peanuts etc. Metadichol acts as inverse/protean agonist on nuclear vitamin D receptors (VDR) that are present in cells throughout the body to stimulate the immune system. Metadichol is a class of unique nanoemulsion molecules that are active against in-vitro viruses, bacteria and parasites. In assays, metadichol showed no cytotoxicity and strongly inhibited cell death caused by each of the pathogens tested. It is a safe and effective inhibitor of various human pathogens. In addition to acting on VDR it shows cross reactivity against other nuclear receptors. And how this leads to mitigation of infections including gene expression analysis and human clinical case studies will be presented. Because it consists of natural components of conventional foods and has no known negative side effects, it has the potential to serve as a novel, broad-spectrum treatment against viruses, bacteria and parasites that confront public health today without eliciting a resistance, that is characteristic of the therapeutics in the market today.

Biography :

P R Raghavan is the CEO of Nanorx Inc. He has completed his PhD in Organic Chemistry from Oregon State University and MS in Chemistry from IIT Mumbai, India. He has worked on drug discovery for over 25 years at Columbia University, Max-Planck Institute, Germany, Ciba-Geigy (now Novartis) and Boehringer Ingelheim. He has over 15 US and international patents and another 15 pending patent applications.